ESTRO 2024 - Abstract Book

S42 ESTRO 2024 upright treatment prior to installation of the beamline components could offer significant advantages and increased capabilities to upright treatments. Effective implementation of such a paradigm shift in treatment delivery requires exceptional teamwork. Therapists, physicists and physicians must work together to set appropriate expectations and understand all limitation of their system. Ongoing adaptation of methods to exploit strengths and mitigate weaknesses is an essential component to ongoing success. Invited Speaker

3348

How to test dose-painting in a clinical trial

Jan-Jakob Sonke

The Netherlands Cancer Institute, Department of Radiation Oncology, Amsterdam, Netherlands

Abstract:

The concept of dose-painting was introduced more than 25 years ago. Dose-painting was inspired by the insight that tumors are spatially heterogeneous as reflected by medical images and the emerging ability to plan and deliver intensity modulated dose distributions through IMRT. Dose-painting then aims to deliver a higher dose to regions of the tumor that are more radio-resistant and a lower dose to regions that are more radio-sensitive resulting in a biological conformal dose distribution. This presentation focuses on how to test the dose painting hypothesis in clinical trials. We will discuss dose painting strategies, methodological challenges, quality assurance and completed and ongoing trials.

3349

HPV-negative oropharynx cancer: The neglected disease

Pernille Lassen

Aarhus University Hospital, Department of Experimental Clinical Oncology, Aarhus, Denmark. Herlev Hospital, Copenhagen University, Department of Oncology, Copenhagen, Denmark

Abstract:

The incidence of oropharyngeal squamous cell carcinoma (OPSCC) in Denmark has increased more than fourfold for both men and women during the past 35 years. This development is primarily driven by a rise in tumours with Human papillomavirus (HPV)-related p16-expression, and Denmark is a high-incidence area of HPV-related disease as these tumours constitute approximately 70% of newly diagnosed OPSCC. The differences in aetiology result in distinct genomic and molecular differences between HPV-positive and HPV-negative tumours, in turn affecting treatment response and survival of the patients. In addition, the more favourable risk factor profile and a better general health status for patients with HPV-related tumours, contribute to significantly improved outcomes for these patients following radiotherapy/chemoradiotherapy (RT/CRT), when compared to HPV-negative patients.